Biologic drugs, including monoclonal antibodies are revolutionizing the treatment of human diseases. There are nearly 60 antibodies that are approved and over 300 or more biologic drugs are at various stages of drug development. And with the improved efficacy and growing number of disease targets for biologic drugs, these numbers are likely to continue to increase.
With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins. These formats are expanding the biologics world and new treatment modalities, however, these new formats have increased challenges for drug development.
Join us for this presentation to learn:
- Market opportunity (and benefits) of biologic drug development
- Challenges to developing novel therapeutics
- Best practices to overcoming biologic development bottlenecks
Rakesh Dixit, PhD, DABT
VP, R&D / Global Head, Biologics Safety